Coverage of Gene Therapies: Balancing Cost, Clinical Impact, and Durability of Effect

Ryan Haumschild, PharmD, MS, MBA, leads a discussion on factors that influence coverage of non-oncology gene therapies, exploring the balance between long-term cost savings and high initial prices, patient selection, and the durability of effect for these therapies.

Related Keywords

Kimberlyc Chen ,Emma Ciafaloni ,Mary Pak ,Ryan Haumschild ,Peer Exchange ,Jessica Nance ,Collaboration ,Gene Therapy ,Managed Care ,Patient Access ,Healthcare ,Clinical Data ,Rare Diseases ,Treatment Options ,Ethical Implications ,Cost Effectiveness ,Equity ,Coverage Determinations , ,Clinical Evidence ,Patient Population ,Financial Sustainability ,Subscription Models ,Warranty Programs ,Performance Based Contracts ,Value Based Contracting ,Patient Advocacy ,Research And Development ,Innovative Therapies ,Communication ,Data Sharing ,Equitable Access ,Patient Centered Care ,Provider Collaboration ,Payer Perspectives ,Treatment Affordability ,Health System Strategies ,